AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|
3.9 C
New York
Saturday, November 14, 2026

Tag: year

newsFORsourcecompanycontentinformationreleases1IT

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action 
NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To...

Scatec signs PPA for 900MW onshore wind project in Egypt

Oslo/Cairo, 15 June 2025: Scatec ASA, a leading renewable energy solutions provider, has signed a USD-denominated 25-year Power Purchase Agreement (PPA) with the Egyptian Electricity Transmission Company (EETC) for a 900 MW wind project, through its dedicated project company “Shadwan Wind Power SAE” to accelerate Egypt’s transition towards a greener and more sustainable energy mix.

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial close for the “Obelisk” hybrid solar and battery storage project in Egypt.

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Unlock Your Wealth: Smart AI and Crypto Investments for Confident Women

Hey lovely money mavens! 🌟 Let's chat about two exciting opportunities in the investment world that could seriously boost your financial game. We're diving...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsYear

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers